Topical Epirubicin as Treatment of in Situ Bladder Carcinoma

1992 ◽  
Vol 59 (1) ◽  
pp. 83-85
Author(s):  
G. Pegoraro ◽  
C. Bondavalli ◽  
B. Dall'Oglio ◽  
L. Schiavon ◽  
M. Luciano ◽  
...  
Keyword(s):  
Complete Remission ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Urinary Cytology ◽  
Control Therapy ◽  
Grade 3

15 patients with primitive carcinoma in situ of the bladder were administered 50 mg/week of Epirubicin; 14 responded to this control therapy with negative urinary cytology and biopsies within an average of 25.6 months. After an average follow up of 47.7 months, 8 out of the 15 patients are still in a state of complete remission, 1 has a recurrent grade 3 carcinoma, 5 are in progression (3 T1 and 2 T2) and 1 has a grade 2 Ta recurrence. 3 patients died from the disease.

Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up

1994 ◽  
Vol 26 (4) ◽  
pp. 437-442 ◽  
Author(s):  
R. Minervini ◽  
R. Felipetto ◽  
L. Vigano ◽  
M. Cecchi
Keyword(s):  
Mitomycin C ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Long Term Follow Up

scholarly journals RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation

2015 ◽  
Vol 33 (7) ◽  
pp. 709-715 ◽  
Author(s):  
Beryl McCormick ◽  
Kathryn Winter ◽  
Clifford Hudis ◽  
Henry Mark Kuerer ◽  
Eileen Rakovitch ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
The United States ◽  
Prospective Randomized Trial ◽  
Grade 3 ◽  
Good Risk

Purpose The Radiation Therapy Oncology Group 9804 study identified good-risk patients with ductal carcinoma in situ (DCIS), a breast cancer diagnosis found frequently in mammographically detected cancers, to test the benefit of radiotherapy (RT) after breast-conserving surgery compared with observation. Patients and Methods This prospective randomized trial (1998 to 2006) in women with mammographically detected low- or intermediate-grade DCIS, measuring less than 2.5 cm with margins ≥ 3 mm, compared RT with observation after surgery. The study was designed for 1,790 patients but was closed early because of lower than projected accrual. Six hundred thirty-six patients from the United States and Canada were entered; tamoxifen use (62%) was optional. Ipsilateral local failure (LF) was the primary end point; LF and contralateral failure were estimated using cumulative incidence, and overall and disease-free survival were estimated using the Kaplan-Meier method. Results Median follow-up time was 7.17 years (range, 0.01 to 11.33 years). Two LFs occurred in the RT arm, and 19 occurred in the observation arm. At 7 years, the LF rate was 0.9% (95% CI, 0.0% to 2.2%) in the RT arm versus 6.7% (95% CI, 3.2% to 9.6%) in the observation arm (hazard ratio, 0.11; 95% CI, 0.03 to 0.47; P < .001). Grade 1 to 2 acute toxicities occurred in 30% and 76% of patients in the observation and RT arms, respectively; grade 3 or 4 toxicities occurred in 4.0% and 4.2% of patients, respectively. Late RT toxicity was grade 1 in 30%, grade 2 in 4.6%, and grade 3 in 0.7% of patients. Conclusion In this good-risk subset of patients with DCIS, with a median follow-up of 7 years, the LF rate was low with observation but was decreased significantly with the addition of RT. Longer follow-up is planned because the timeline for LF in this setting seems protracted.

Contemporary outcomes of bladder carcinoma in situ treated with an adequate BCG immunotherapy

2021 ◽  
Author(s):  
José Daniel Subiela ◽  
Óscar Rodríguez Faba ◽  
Júlia Aumatell ◽  
Julio Calderón ◽  
Asier Mercadé ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Bcg Immunotherapy

Cyclin D3 gene amplification in bladder carcinoma in situ

2010 ◽  
Vol 457 (5) ◽  
pp. 555-561 ◽  
Author(s):  
Antonio Lopez-Beltran ◽  
Jose L. Ordóñez ◽  
Ana P. Otero ◽  
Ana Blanca ◽  
Vicky Sevillano ◽  
...  
Keyword(s):  
Gene Amplification ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Cyclin D3

1034 CLINICAL OUTCOMES OF PRIMARY BLADDER CARCINOMA IN SITU IN A CONTEMPORARY SERIES

2010 ◽  
Vol 9 (2) ◽  
pp. 324
Author(s):  
D. Chade ◽  
S.F. Shariat ◽  
G. Godoy ◽  
C. Savage ◽  
A. Cronin ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Primary Bladder

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

2006 ◽  
Vol 24 (21) ◽  
pp. 3381-3387 ◽  
Author(s):  
Nina Bijker ◽  
Philip Meijnen ◽  
Johannes L. Peterse ◽  
Jan Bogaerts ◽  
Irène Van Hoorebeeck ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Phase Iii ◽  
Breast Conserving Treatment ◽  
European Organisation ◽  
Radiotherapy Group ◽  
Long Term Follow Up

Purpose The European Organisation for Research and Treatment of Cancer conducted a randomized trial investigating the role of radiotherapy (RT) after local excision (LE) of ductal carcinoma-in-situ (DCIS) of the breast. We analyzed the efficacy of RT with 10 years follow-up on both the overall risk of local recurrence (LR) and related to clinical, histologic, and treatment factors. Patients and Methods After complete LE, women with DCIS were randomly assigned to no further treatment or RT (50 Gy). One thousand ten women with mostly (71%) mammographically detected DCIS were included. The median follow-up was 10.5 years. Results The 10-year LR-free rate was 74% in the group treated with LE alone compared with 85% in the women treated by LE plus RT (log-rank P < .0001; hazard ratio [HR] = 0.53). The risk of DCIS and invasive LR was reduced by 48% (P = .0011) and 42% (P = .0065) respectively. Both groups had similar low risks of metastases and death. At multivariate analysis, factors significantly associated with an increased LR risk were young age (≤ 40 years; HR = 1.89), symptomatic detection (HR = 1.55), intermediately or poorly differentiated DCIS (as opposed to well-differentiated DCIS; HR = 1.85 and HR = 1.61 respectively), cribriform or solid growth pattern (as opposed to clinging/micropapillary subtypes; HR = 2.39 and HR = 2.25 respectively), doubtful margins (HR = 1.84), and treatment by LE alone (HR = 1.82). The effect of RT was homogeneous across all assessed risk factors. Conclusion With long-term follow-up, RT after LE for DCIS continued to reduce the risk of LR, with a 47% reduction at 10 years. All patient subgroups benefited from RT.

Lobular carcinoma in situ of the breast Detailed analysis of 99 patients with average follow-up of 24 years

1978 ◽  
Vol 2 (3) ◽  
pp. 225-252 ◽  
Author(s):  
Paul Peter Rosen ◽  
Philip H. Lieberman ◽  
David W. Braun ◽  
Cynthia Kosloff ◽  
Frank Adair
Keyword(s):  
Detailed Analysis ◽  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Lobular Carcinoma In Situ

scholarly journals Ductal carcinoma in situ presenting as a cystic retroareolar lesion in an African American man

2021 ◽  
Author(s):  
Amara Ndumele ◽  
Amy Kerger ◽  
Gary Tozbikian ◽  
Samilia Obeng-Gyasi ◽  
Bridget Oppong
Keyword(s):  
African American ◽  
Health Outcomes ◽  
Chest Wall ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Cystic Lesion ◽  
Ductal Carcinoma ◽  
Unusual Finding

We report an unusual finding of DCIS within a cystic lesion in a black man highlighting the need for adequate workup, and timely follow-up for men with breast/chest wall masses given the lack of screening in this population. Furthermore, we will explore how race contributes to prognosis and health outcomes.

Sign in / Sign up

Export Citation Format

Share Document